Streetbeat News

Analyst Ratings

CF

Wells Fargo has maintained an Overweight rating on CF Industries Holdings and raised its price target from $88 to $92, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:07 pm

COGT

Citigroup analyst David Lebowitz maintains a Buy rating on Cogent Biosciences and raises the price target from $13 to $15.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:02 pm

INVH

Invitation Homes (NYSE:INVH) has been evaluated by 15 analysts over the past three months, showing a range of sentiments from bullish to bearish. The average 12-month price target is $38.53, up 2.75% from the previous target. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions. Invitation Homes owns a large portfolio of single-family rental homes, with strong revenue growth and a solid financial structure, but faces challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:01 pm

V

Financial giants are showing a bullish sentiment towards Visa, with 73% of options traders betting positively. The price target for Visa is between $155 and $285, with significant options activity noted. Visa's stock is currently down by 4.07%, with a consensus target price of $314.67 from analysts.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:01 pm

TRIP

Citigroup analyst Ronald Josey maintains a Neutral rating on Tripadvisor and lowers the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:00 pm

PCRX

Pacira BioSciences (NASDAQ:PCRX) has received mixed analyst ratings, with a notable decrease in the average 12-month price target from $41.29 to $30.36. Analysts have adjusted their ratings and price targets, reflecting varied expectations for the company's future performance. Despite a strong net margin and effective debt management, Pacira's revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:00 pm

OKTA

Analysts have recently adjusted their ratings and price targets for Okta (NASDAQ:OKTA), with a general trend of lowering expectations. The average 12-month price target has decreased by 8.82% to $105.64. Despite this, Okta shows strong financial health with impressive revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:00 pm

EL

Estee Lauder Cos (NYSE:EL) has received mixed analyst ratings over the past three months, with a recent average 12-month price target of $120.91, down from $137.97. Analysts have adjusted their ratings and price targets in response to market dynamics, with some maintaining bullish stances while others have lowered their expectations. Estee Lauder's financial performance shows a revenue growth rate of 7.26% and challenges in debt management with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:00 pm

HD

LOW

Oppenheimer analyst Brian Nagel upgraded Lowe's Companies Inc (NYSE:LOW) from Perform to Outperform, raising the price target from $230 to $305. The upgrade is based on expected demand improvements in the home improvement sector due to moderating lending rates, with benefits likely to be seen starting in 2025. Lowe's shares rose 0.63% following the announcement.

Portfolio Pulse from Priya Nigam

September 24, 2024 | 3:58 pm

BA

EADSY

TGI

Triumph Group Inc (NYSE:TGI) has been downgraded by BofA Securities due to uncertainties in aircraft production rates from Boeing and Airbus. The downgrade includes a rating change from Buy to Underperform and a price target reduction from $17 to $12. Concerns include production rates, free cash flow risks, and potential destocking.

Portfolio Pulse from Priya Nigam

September 24, 2024 | 3:54 pm